Literature DB >> 22569680

Current status and future perspectives of patient-reported outcome research in clinical trials for patients with breast cancer in Japan.

Shozo Ohsumi1, Kojiro Shimozuma.   

Abstract

The aim of healthcare providers is to help patients regain their health and/or maintain or increase their happiness. The quality of healthcare can be assessed objectively by using indices such as survival rates, but subjective assessment is sometimes more important than objective evaluation, because whether patients feel healthy or happy or not is their major concern. Quality of life (QOL) research is a typical approach to subjective assessment of health. Self-administered health-related QOL (HRQOL) questionnaires are used to obtain patient-reported outcome (PRO) data. PRO is defined by the US Food and Drug Administration (FDA) as any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else. PRO data are regarded as more accurate than clinician-rated ones in terms of assessing patients' symptoms and HRQOL. The Comprehensive Support Project for Health Outcome Research of the Public Health Research Foundation has conducted much PRO research in collaboration with the Comprehensive Support Project for Oncology Research, especially in randomized controlled trials (RCTs). Here, we review the results of PRO research in RCTs conducted in Japan and examine future perspectives in this field.

Entities:  

Mesh:

Year:  2012        PMID: 22569680     DOI: 10.1007/s12282-012-0368-8

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  3 in total

1.  Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole.

Authors:  Hiroshi Yagata; Hiroshi Ohtsu; Yoshifumi Komoike; Shigehira Saji; Hiroyuki Takei; Toshitaka Nakamura; Yasuo Ohashi; Takuya Iwase; Kojiro Shimozuma
Journal:  Support Care Cancer       Date:  2015-07-08       Impact factor: 3.603

2.  Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.

Authors:  Eriko Aotani; Tetsutaro Hamano; Akihiko Gemma; Masahiro Takeuchi; Toru Takebayashi; Kunihiko Kobayashi
Journal:  Int J Clin Oncol       Date:  2016-02-15       Impact factor: 3.402

Review 3.  Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review.

Authors:  Cathrine Lundgaard Riis; Troels Bechmann; Pernille Tine Jensen; Angela Coulter; Karina Dahl Steffensen
Journal:  Patient Relat Outcome Meas       Date:  2019-03-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.